Ying Shi Biological completes over $34 million C round financing.

On August 22, according to Kunlun Capital, recently, InxMed Limited, an innovative drug research and development company focusing on the treatment of solid tumors, announced the completion of over 34 million US dollars in series C financing. This round of financing was led by Foresite Capital, with participation from Bessemer Venture Partners, ClearVue Partners, Kunlun Capital, and existing shareholders Advantech Capital.